{"id":"telmisartan-plus-metformin","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Gastrointestinal disturbance (metformin-related)"},{"rate":null,"effect":"Hyperkalemia"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL1017","moleculeType":"Small molecule","molecularWeight":"514.63"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Telmisartan is an angiotensin II receptor blocker (ARB) that reduces vasoconstriction and aldosterone secretion, lowering blood pressure. Metformin is a biguanide that decreases hepatic gluconeogenesis and enhances peripheral glucose uptake and insulin sensitivity. This combination addresses both hypertension and hyperglycemia in patients with concurrent conditions.","oneSentence":"Telmisartan blocks angiotensin II receptors to lower blood pressure, while metformin reduces hepatic glucose production and improves insulin sensitivity to control blood sugar.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:38:27.371Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension in patients with type 2 diabetes mellitus"},{"name":"Cardiovascular risk reduction in hypertensive diabetic patients"}]},"trialDetails":[{"nctId":"NCT06515652","phase":"NA","title":"To Compare the Effects of Herbal Medicines With Traditional Allopathic Medicines in Cases of Patients With Metabolic Syndrome","status":"RECRUITING","sponsor":"Hamdard University","startDate":"2023-09-01","conditions":"Metabolic Syndrome","enrollment":200},{"nctId":"NCT00486187","phase":"NA","title":"Effects of ROSIglitazone on Inflammatory Markers and Adipokines in Diabetic Patients Using an Angiotensin Receptor Blocker (TELmisartan) - The ROSITEL Study","status":"COMPLETED","sponsor":"Dr. Milan Gupta","startDate":"2006-04","conditions":"Type 2 Diabetes Mellitus","enrollment":103},{"nctId":"NCT00538486","phase":"PHASE4","title":"A Randomized, Double-Blind, Active Control Trial Comparing Effects of Telmisartan, Candesartan and Amlodipine, Alone or Plus Metformin, on Non-Diabetic, Obese Hypertensive Patients","status":"COMPLETED","sponsor":"Third Military Medical University","startDate":"2008-02","conditions":"Hypertension, Obesity","enrollment":360}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Telmisartan plus Metformin","genericName":"Telmisartan plus Metformin","companyName":"Third Military Medical University","companyId":"third-military-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Telmisartan blocks angiotensin II receptors to lower blood pressure, while metformin reduces hepatic glucose production and improves insulin sensitivity to control blood sugar. Used for Hypertension in patients with type 2 diabetes mellitus, Cardiovascular risk reduction in hypertensive diabetic patients.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}